CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY) Stock Overview
Explore CymaBay Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.7B
P/E Ratio
-32.74
EPS (TTM)
$-0.99
ROE
-0.64%
CBAY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of CymaBay Therapeutics, Inc. (CBAY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $65.69.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -32.74 and a market capitalization of 3.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.